CervoMed Inc. financial data

Symbol
CRVO on Nasdaq
Location
20 Park Plaza, Suite 424, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 12.8 % +18.4%
Return On Equity 130 % +2223%
Return On Assets -68.1 % -71%
Operating Margin -442 % -230%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.25M shares +12.1%
Common Stock, Shares, Outstanding 9.25M shares +12.1%
Entity Public Float 91.6M USD
Common Stock, Value, Issued 9.25K USD +12.1%
Weighted Average Number of Shares Outstanding, Basic 9.25M shares +6.32%
Weighted Average Number of Shares Outstanding, Diluted 8.7M shares +131%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.16M USD -38.8%
Research and Development Expense 23.1M USD +58.4%
General and Administrative Expense 10.3M USD +14.8%
Operating Income (Loss) -27.2M USD -102%
Nonoperating Income (Expense) 1.62M USD +6.56%
Net Income (Loss) Attributable to Parent -25.6M USD -114%
Earnings Per Share, Basic -2 USD/shares -368%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.44M USD +21.9%
Marketable Securities, Current 17.9M USD -54.1%
Cash, Cash Equivalents, and Short-term Investments 27.3M USD
Other Assets, Current 49.8K USD -33%
Assets, Current 30.6M USD -37.3%
Other Assets, Noncurrent 0 USD -100%
Assets 30.6M USD -37.4%
Accounts Payable, Current 1.35M USD +24.6%
Employee-related Liabilities, Current 1.01M USD +36.8%
Liabilities 4.6M USD +41.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5.82K USD -95.3%
Retained Earnings (Accumulated Deficit) -89.6M USD -40%
Stockholders' Equity Attributable to Parent 26M USD -43%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.34M USD
Liabilities and Equity 30.6M USD -37.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.89M USD -174%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 5.4M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 9.25M shares +12.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.5M USD +64.9%
Deferred Tax Assets, Gross 18.9M USD +32.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.7M USD -210%
Deferred Tax Assets, Operating Loss Carryforwards 10.4M USD -0.75%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 116M USD +5.55%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 18.6M USD +31.6%
Share-based Payment Arrangement, Expense 1.49M USD +20.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares